Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data

Early outcomes of migraine after erenumab discontinuation: data from a real-life setting

(2021) Eleonora De Matteis et al.   NEUROLOGICAL SCIENCES

Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study

(2021) Maria Michela Cainazzo et al.   NEUROLOGICAL SCIENCES

Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment – a real-life cohort study

(2021) Andreas R Gantenbein et al.   CEPHALALGIA

The Evolution of Medication Overuse Headache: History, Pathophysiology and Clinical Update

(2021) Christina Sun-Edelstein et al.   CNS DRUGS

Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)

(2021) Fabrizio Vernieri et al.   JOURNAL OF HEADACHE AND PAIN

Chronic Migraine and Medication Overuse Headache Worsening After OnabotulinumtoxinA Withdrawn Due to the Severe Acute Respiratory Syndrome-Coronavirus-2 Pandemic

(2021) Carlo Baraldi et al.   Frontiers in Neurology

Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study

(2021) Bianca Raffaelli et al.   CEPHALALGIA

Short and Mid‐Term Predictors of Response to OnabotulinumtoxinA: Real‐Life Experience Observational Study

(2020) Alicia Alpuente et al.   HEADACHE

Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives

(2020) Eleonora De Matteis et al.   Expert Review of Neurotherapeutics

Plasma levels of CGRP and expression of specific microRNAs in blood cells of episodic and chronic migraine subjects: towards the identification of a panel of peripheral biomarkers of migraine?

(2020) Rosaria Greco et al.   JOURNAL OF HEADACHE AND PAIN

A proof-of-concept study on CGRP plasma levels of migraineurs during a 6-month treatment with ERENUMAB

(2020) Giuseppe Tringali et al.   JOURNAL OF HEADACHE AND PAIN

European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

(2019) Simona Sacco et al.   JOURNAL OF HEADACHE AND PAIN

Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination

(2019) Bianca Raffaelli et al.   JOURNAL OF HEADACHE AND PAIN

Cortical spreading depression as a site of origin for migraine: Role of CGRP

(2018) Liesl N Close et al.   CEPHALALGIA

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

(2018)   CEPHALALGIA

Feasibility of serum CGRP measurement as a biomarker of chronic migraine: a critical reappraisal

(2018) Mi Ji Lee et al.   JOURNAL OF HEADACHE AND PAIN

Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

(2017) Theo Vos et al.   LANCET

Diet-induced obesity alters dural CGRP release and potentiates TRPA1-mediated trigeminovascular responses

(2016) Balázs Marics et al.   CEPHALALGIA

Medication-overuse headache: risk factors, pathophysiology and management

(2016) Hans-Christoph Diener et al.   Nature Reviews Neurology

Treatment of medication-overuse headache: A systematic review

(2015) Chia-Chun Chiang et al.   CEPHALALGIA

Critical role of calcitonin gene-related peptide receptors in cortical spreading depression

(2012) A. Tozzi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Migraine Chronification

(2011) Marcelo E. Bigal et al.   Current Neurology and Neuroscience Reports

Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraine

(2010) Min Yang et al.   CEPHALALGIA